WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Corporation (Nasdaq:INCY) announced today that it has scheduled a webcast and conference call for 10:30 p.m. Eastern Time / 7:30 p.m. Pacific Time on Sunday, October 26, 2008 to discuss clinical results from a Phase IIa trial of INCB18424, its oral JAK 1&2 inhibitor, in patients with rheumatoid arthritis. Results from the Phase IIa trial will be presented at the 2008 American College of Rheumatology (ACR) Annual Scientific Meeting that is being held in San Francisco (details below):
